Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz(University of Miami), John Sweetenham(Cleveland Clinic), Julie Lisano(Seagen (United States)), Andy I. Chen(Scripps Research Institute), Edward Agura(Baylor University Medical Center), Muneer H. Abidi(Spectrum Health), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Teresa McClendon(Seagen (United States)), Veronika Bachanová(University of Minnesota), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Jerzy Hołowiecki(Medical University of Silesia), Tamás Masszi, Simonetta Viviani(Fondazione IRCCS Istituto Nazionale dei Tumori), Auayporn Nademanee(City Of Hope National Medical Center), Connie Lee(University of Michigan), Patrick J. Stiff(Loyola University Medical Center)
Cited by 250
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k